These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9600792)

  • 1. Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment: prediction of bone mass changes during treatment.
    Ravn P; Christensen JO; Baumann M; Clemmesen B
    Bone; 1998 May; 22(5):559-64. PubMed ID: 9600792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect on bone mass and bone markers of different doses of ibandronate: a new bisphosphonate for prevention and treatment of postmenopausal osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study.
    Ravn P; Clemmesen B; Riis BJ; Christiansen C
    Bone; 1996 Nov; 19(5):527-33. PubMed ID: 8922653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral weekly ibandronate prevents bone loss in postmenopausal women.
    Tankó LB; Felsenberg D; Czerwiński E; Burdeska A; Jonkanski I; Hughes C; Christiansen C;
    J Intern Med; 2003 Aug; 254(2):159-67. PubMed ID: 12859697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women.
    Stakkestad JA; Benevolenskaya LI; Stepan JJ; Skag A; Nordby A; Oefjord E; Burdeska A; Jonkanski I; Mahoney P;
    Ann Rheum Dis; 2003 Oct; 62(10):969-75. PubMed ID: 12972476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Alendronate Osteoporosis Prevention Study Group.
    Ravn P; Clemmesen B; Christiansen C
    Bone; 1999 Mar; 24(3):237-44. PubMed ID: 10071916
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis.
    McClung MR; Wasnich RD; Recker R; Cauley JA; Chesnut CH; Ensrud KE; Burdeska A; Mills T;
    J Bone Miner Res; 2004 Jan; 19(1):11-8. PubMed ID: 14753731
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis.
    Ravn P; Neugebauer G; Christiansen C
    Bone; 2002 Jan; 30(1):320-4. PubMed ID: 11792604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infusion of ibandronate once every 3 months effectively decreases bone resorption markers and increases bone mineral density in Chinese postmenopausal osteoporotic women: a 1-year study.
    Li M; Xing XP; Zhang ZL; Liu JL; Zhang ZL; Liu DG; Xia WB; Meng XW
    J Bone Miner Metab; 2010 May; 28(3):299-305. PubMed ID: 19855926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL; Parker RA; Ferguson L; Rosen HN; Maitland-Ramsey L; Karpf DB
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES; Binkley NC; Lewiecki EM; Gruntmanis U; Fries MA; Dasic G
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R; Delmas PD; Bolognese M; Borges JL; Cosman F; Ragi-Eis S; Recknor C; Zerbini CA; Neate C; Sedarati F; Epstein S
    Clin Ther; 2009 Apr; 31(4):751-61. PubMed ID: 19446148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monthly Oral Ibandronate Reduces Bone Loss in Korean Women With Rheumatoid Arthritis and Osteopenia Receiving Long-term Glucocorticoids: A 48-week Double-blinded Randomized Placebo-controlled Investigator-initiated Trial.
    Shin K; Park SH; Park W; Baek HJ; Lee YJ; Kang SW; Choe JY; Yoo WH; Park YB; Song JS; Lee SG; Yoo B; Yoo DH; Song YW
    Clin Ther; 2017 Feb; 39(2):268-278.e2. PubMed ID: 28161119
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L; Buus NH; Vestergaard P; Heickendorff L; Andreasen F; Larsen ML; Mosekilde L
    J Bone Miner Res; 2004 May; 19(5):737-44. PubMed ID: 15068496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women.
    Chaki O; Yoshikata I; Kikuchi R; Nakayama M; Uchiyama Y; Hirahara F; Gorai I
    J Bone Miner Res; 2000 Aug; 15(8):1537-44. PubMed ID: 10934652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary hyperparathyroidism: biochemical markers and bone mineral density at multiple skeletal sites in Danish patients.
    Christiansen P; Steiniche T; Brixen K; Hessov I; Melsen F; Charles P; Mosekilde L
    Bone; 1997 Jul; 21(1):93-9. PubMed ID: 9213014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial.
    Marcus R; Holloway L; Wells B; Greendale G; James MK; Wasilauskas C; Kelaghan J
    J Bone Miner Res; 1999 Sep; 14(9):1583-95. PubMed ID: 10469288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation.
    Smerud KT; Dolgos S; Olsen IC; Åsberg A; Sagedal S; Reisæter AV; Midtvedt K; Pfeffer P; Ueland T; Godang K; Bollerslev J; Hartmann A
    Am J Transplant; 2012 Dec; 12(12):3316-25. PubMed ID: 22946930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical bone markers and bone mineral density during postmenopausal hormone replacement therapy with and without vitamin D3: a prospective, controlled, randomized study.
    Heikkinen AM; Parviainen M; Niskanen L; Komulainen M; Tuppurainen MT; Kröger H; Saarikoski S
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2476-82. PubMed ID: 9253321
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.